Chemours Company (The) Common Stock (CC)

In the high-stakes world of hedge fund management, few strategies are as nerve-wracking—or potentially lucrative—as the contrarian "deep value" play. This month, the spotlight has fallen on Alta Fundamental Advisers, a New York-based firm led by Nicholas S. Danaher, which has disclosed a massive new position in The

Calumet just posted eye-catching profits, but one fund still headed for the exits.

Here's why one New York fund just scooped up 800,000 shares of The Chemours Company.

This exit shows exactly where some investors might think the pressure is building for this stock.

One hedge fund just made a bold bet on a beaten-down chemicals giant—here’s what long-term investors should know.

The cryptocurrency market is buzzing with the highly anticipated debut of several spot XRP Exchange-Traded Funds (ETFs), which have collectively surged towards an impressive $1 billion in assets under management (AUM) since their mid-November 2025 launch. This monumental inflow of capital, occurring within weeks of their introduction, marks a pivotal moment for the XRP ecosystem [...]

One industrial supplier just posted a record year—and a concentrated fund quietly built a new stake.

One fund just made a contrarian bet on an industrial turnaround story—here’s what long-term investors should watch next.

Chemours (CC) missed Q3 2025 earnings estimates, with EPS of $0.20 vs. $0.26 expected. Strong Opteon™ sales were offset by weak performance in other segments and a cautious Q4 outlook.

Industrial stocks have started to pick up the pace in terms of price action, yet they are not even close to pricing in the growth potential

Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid falling crop prices and rising costs.

DuPont agreed to sell its Aramids business, including Kevlar and Nomex brands, to Arclin for $1.8B. Deal aligns with DuPont's strategy to improve profitability and shareholders to benefit from Arclin's growth.